Our findings were consistent with these observations that BRAF-mutated NSCLC patients have similar responses to ICI monotherapy compared to WT BRAF. Further, our results also unveiled that ICIs combined with chemotherapy or anti-angiogenesis regimens had similar objective response rates or survival regardless of BRAF mutations. Here, BRAF is linked to non-small cell lung carcinoma.